Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 16, 2008
Impact of basolateral multidrug resistance-associated protein (Mrp) 3 and Mrp4 on the hepatobiliary disposition of fexofenadine in perfused mouse liversXianbin Tian, Brandon Swift, Maciej J Zamek-Gliszczynski, et al.
Sexually Transmitted Infections|November 21, 2022
Dose selection for a phase III study evaluating gepotidacin (GSK2140944) in the treatment of uncomplicated urogenital gonorrhoeaNicole E Scangarella-Oman, Mohammad Hossain, Caroline R Perry, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 23, 2024
Serum bile acid change correlates with improvement in pruritus in patients with primary biliary cholangitis receiving linerixibatEleni Karatza, Brandon Swift, Fernando Carreño, et al.
Clinical and Translational Science|January 16, 2023
Clinical assessment of gepotidacin (GSK2140944) as a victim and perpetrator of drug-drug interactions via CYP3A metabolism and transportersAline Barth, Caroline R Perry, Shaila Shabbir, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 14, 2013
Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolitesBrandon Swift, Noelia Nebot, Jin Kyung Lee, et al.
Clinical Pharmacology in Drug Development|December 5, 2022
Pharmacokinetic, Safety, and Tolerability Evaluations of Gepotidacin (GSK2140944) in Healthy Japanese ParticipantsAline Barth, Mohammad Hossain, Caroline R Perry, et al.
Journal of Clinical and Experimental Hepatology|April 21, 2025
Serum Bile Acid Elevation is an Independently Associated With Pruritus in Patients With At-risk Metabolic Dysfunction-associated Steatotic Liver DiseaseZobair M Younossi, Michael J Estep, Sean Felix, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 7, 2022
GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With PruritusCynthia Levy, Stuart Kendrick, Christopher L Bowlus, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 9, 2021
Pharmacokinetics and ADME Characterization of Intravenous and Oral [14C]-Linerixibat in Healthy Male VolunteersMaciej J Zamek-Gliszczynski, David Kenworthy, David A Bershas, et al.
The Lancet. Gastroenterology & Hepatology|October 31, 2025
Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trialGideon M Hirschfield, Christopher L Bowlus, David E J Jones, et al.
Pageof 2